Companies Also Sign Investor Rights Agreement
TSX: ACB
TSXV: RTI
VANCOUVER, Nov. 6, 2017 /CNW/ - Further to the two companies'
joint press release of October 23, 2017, Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX:
ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM)) and Radient Technologies Inc. ("Radient")
(TSXV: RTI) today announced the companies have finalized a Master Services Agreement (the "Agreement"), pursuant to which Radient
has agreed to perform certain services for Aurora using its proprietary MAP™ technology, as well as other technologies, as an
independent contractor in relation to the development, commercialization and supply of standardized cannabis extracts. The
Agreement has an initial term of five years, with an option for Aurora to renew the agreement for an additional five years.
Under the terms of the agreement, Radient will provide processing services to Aurora for the production of extracts from
material supplied by the Company, which may include both cannabis and hemp. The agreement initially covers services delivered in
Canada, Australia, and the European Union, including
Germany where Aurora's wholly owned subsidiary Pedanios is the largest distributor of medical
cannabis on the continent. Additionally, Aurora has the right to negotiate on an exclusive basis with Radient to expand the
jurisdictions covered. Within the countries covered by the agreement, Radient shall deliver its services under preferential terms
to Aurora.
Radient applied in December, 2016 to Health Canada to obtain Licensed Dealer status, and in February, 2017 for Licensed
Producer status, and is progressing well through the processes. Upon receipt of either license, Radient will be able to commence
production of cannabis extracts from products supplied by Aurora or Aurora's partners.
"This agreement will enable us, in the very near future, to dramatically accelerate the production of high-margin cannabis
derivatives under favourable terms," said Terry Booth, CEO. "The market for non-smoked derivative
cannabis products is growing at a remarkable pace, and through this agreement we have a cost-effective and scalable means to help
meet this demand - particularly once we begin harvests in the first half of 2018 at our 100,000+ kg per annum Aurora Sky
production facility. We intend to continue our collaboration with Radient on other R&D projects that we expect will deliver
significant value to both companies."
Denis Taschuk, CEO of Radient, added, "This agreement brings together the industry's most
technologically advanced cultivation facility, Aurora Sky, with the industry's most advanced extraction platform, Radient's
MAP™. With a shared commitment to world-leading quality assurance and the development of innovative products, we are
excited about the benefits this partnership will bring to our respective stakeholders."
The Master Services Agreement includes an Investor Rights Agreement that provides Aurora with certain rights to participate in
future offerings, providing Aurora with the option to expand its ownership in Radient up to 19.99%. Aurora also has the
right to appoint one director to the Radient Board of Directors.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to
Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot,
state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora
Mountain", a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island, and is currently
constructing an 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton
International Airport.
In addition, the Company holds approximately 9.6% of the issued shares (12.9% on a fully-diluted basis) in leading extraction
technology company Radient Technologies Inc., based in Edmonton, and is in the process of
completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to
50.1%. Furthermore, Aurora is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company
licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer,
exporter, and distributor of medical cannabis in the European Union, based in Germany. The
Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry
leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor
cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens,
vegetables and herbs in home and professional kitchens. Aurora's common shares trade on the TSX under the symbol "ACB".
About Radient
Radient extracts natural compounds from a range of biological materials using its proprietary MAPTM natural product
extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its
initial 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market
leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit
www.radientinc.com for more information.
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
RADIENT TECHNOLOGIES INC.
Denis Taschuk,
CEO
Information set forth in this news release contains forward-looking information and statements that are based on
assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and
expectations. They are not guarantees of future performance. The terms and phrases "goal", "commitment", "guidance", "expects",
"would", "will", "continuing", "drive", "believes", "indicate", "look forward", "grow", "outlook", "forecasts", "intend", and
similar terms and phrases are intended to identify these forward-looking statements. The Corporations caution that all forward
looking information and statements are inherently uncertain and that actual performance may be affected by a number of material
factors, many of which are beyond the Corporations' control. Such factors include, among other things: risks and uncertainties
relating to the Corporations' ability to finalize the terms of the proposed agreement. Accordingly, actual and future events,
conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the
forward looking information. Except as required under applicable securities legislation, the Corporations undertake no obligation
to publicly update or revise forward-looking information.
Neither TSX nor TSX Venture Exchange nor their Regulation Services Providers (as that term is defined in the policies of
the respective Exchanges) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc.
View original content: http://www.newswire.ca/en/releases/archive/November2017/06/c1444.html